ORR of 67% (6 of 9) in MAPK inhibitor (MAPKi)-naïve adults with V600-mutated primary recurrent central nervous system tumors, with a median duration of response (mDOR) of 13.9 months ORR of 42% (10 of ...

Dabrafenib plus trametinib results in significantly more responses and longer progression-free survival than standard chemotherapy for pediatric patients with low-grade glioma with BRAF V600 mutations ...

PHILADELPHIA--(BUSINESS WIRE)--FORE Biotherapeutics, a registration stage biotherapeutics company dedicated to developing targeted therapies to treat patients with cancer, today presented new ...

The largest known prospective study of patients treated with trametinib plus dabrafenib for unresectable advanced melanoma with BRAF-V600 mutation confirmed the combination’s clinical activity.

If approved, Ojemda® (tovorafenib) is expected to be the first and only targeted medicine in European Union for children with relapsed or ...

Tafinlar plus Mekinist is now approved by the Food and Drug Administration to treat adults and children over the age of 6 who have BRAF V600-mutant advanced solid cancers. The Food and Drug ...

Drug is indicated for patients identified by Roche’s cobas 4800 mutation test. The European Commission approved Roche and Plexxikon’s melanoma drug Zelboraf (vemurafenib) for the treatment of BRAF ...

Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration has approved Opdivo in combination with Yervoy for the treatment of patients with BRAF V600 wild-type and BRAF ...

Cobimetinib Plus Vemurafenib in Patients With Colorectal Cancer With BRAF Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study Mitogen-activating protein kinase ...

Phase 1B study of vemurafenib in combination with irinotecan and cetuximab in patients with BRAF-mutated advanced cancers and metastatic colorectal cancer. This is an ASCO Meeting Abstract from the ...

CHICAGO —Targeted therapy achieved significantly higher responses rates and longer progression-free survival (PFS) when compared with standard chemotherapy in pediatric patients with BRAF V600-mutant ...

Cobimetinib (trade name: Cotellic) has been approved since November 2015 in combination with vemurafenib for the treatment of adults with advanced, i.e. metastatic or unresectable, melanoma with a ...